Indication assessment · §3
Biological ageing and healthspan endpoints — trial records
Trial records in the Institute's register bearing on biological ageing and healthspan endpoints.
§3Trials in this indication
4 trial records in the Institute's register bear on this indication, of which 1 is a published trial.
Table 2. Trial records bearing on biological ageing and healthspan endpoints.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| EPI-RU-ELDERLY | Epithalon | — | Observational | — | — |
| EPI-RU-ELDERLY-PKprogramme record | Epithalon | Phase 1 | Phase 1 ascending dose | — | — |
| EPI-RU-ELDERLY-RENAL-IMPprogramme record | Epithalon | Phase 1 | Phase 1 ascending dose | — | — |
| EPI-RU-ELDERLY-BODY-COMPprogramme record | Epithalon | — | Randomised, double-blind, placebo-controlled | — | — |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009 · PMID 25738459
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-30/3 · https://compoundevidence.com/indications/longevity/trials/ · retrieved 30 July 2026